Skip to main content
U.S. flag

An official website of the United States government

Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice

Bibliographic

Year of Publication:
2006
Contact PI Name:
Timothy J. Seabrook
Contact PI Affiliation:
Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Co-Authors:
L. Jiang, M. Maier, C.A. Lemere
Primary Reference (PubMED ID):
Funding Source:
Alzheimer's Association
American Health Assistance Foundation
Study Goal and Principal Findings:

Activated microglia and reactive astrocytes invade and surround cerebral beta amyloid (Abeta) plaques in Alzheimer's disease (AD), but the role of microglia in plaque development is still unclear. In this study, minocycline was administered for 3 months, prior to and early in Abeta plaque formation in amyloid precursor protein transgenic mice (APP-tg). When minocycline was given to younger mice, there was a small but significant increase in Abeta deposition in the hippocampus, concurrent with improved cognitive performance relative to vehicle treated mice. If APP-tg mice received minocycline after Abeta deposition had begun, microglial activation was suppressed but this did not affect Abeta deposition or improve cognitive performance. In vitro studies demonstrated that minocycline suppressed microglial production of IL-1beta, IL-6, TNF, and NGF. Thus, minocycline has different effects on Abeta plaque deposition and microglia activation depending on the age of administration. Our data suggest that this may be due to the effects of minocycline on microglial function. Therefore, anti-inflammatory therapies to suppress microglial activation or function may reduce cytokine production but enhance Abeta plaque formation early in AD.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
Minocycline
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APP
Strain/Genetic Background:
B6D2

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Histopathology
Activated Microglia
Activated Astrocytes
beta Amyloid Deposits
beta Amyloid Load
Microhemorrhages
Dense-core/Compact Plaques
Biochemical
Cytokines
Interleukin 4 (IL-4)
Interleukin 10 (IL-10)
Interleukin 1 beta (IL-1 beta)
Interleukin 6 (IL-6)
Tumor Necrosis Factor alpha (TNF alpha)
Brain-Derived Neurotrophic Factor (BDNF)
Nerve Growth Factor (NGF)
Glial Cell Derived Neurotrophic Factor (GDNF)
Brain-beta Amyloid Peptide 42
Brain-beta Amyloid Peptide 40
Cell-beta Amyloid Peptide 40
Cell-beta Amyloid Peptide 42
Immunochemistry
Major Histocompatibility Antigens Class 2 (MHC II)
CD45
CD11b
Glial Fibrillary Acidic Protein (GFAP)
Activated Astrocytes
Brain-beta Amyloid Deposits
Cell Biology
Neuroprotection-Amyloid Neurotoxicity
Cytokines